AN2 Therapeutics Q1 FY26 net loss narrows 5.83% to $10 million

AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc.

ANTX

0.00
  • AN2 Therapeutics posted a Q1 net loss of USD 10 million, narrowing from USD 10.6 million a year earlier; loss per share improved to USD 0.29 from USD 0.35.
  • R&D spending fell to USD 6.7 million from USD 7.7 million, while G&A was flat at USD 3.8 million.
  • Interest income slipped to USD 0.5 million from USD 0.9 million on lower average cash balances and lower interest rates.
  • Cash, cash equivalents and investments totaled USD 85.3 million at March 31, following a USD 40 million private placement; cash runway projected into 2029.
  • Plans Phase 2 start for oral epetraborole in polycythemia vera in Q3 2026 with data as early as Q4 2026, expects Phase 1 data for Chagas candidate AN2-502998 in Q2 2026, and targets late-2027 topline results from an investigator-initiated Phase 2 study of epetraborole in M. abscessus lung disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260511281560) on May 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.